Autopsy report · NCT06449482

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

“The number of participants in the study did not meet expectations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 11 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Sponsor type

University, hospital or other

Conditions

Acute Myeloid Leukemia, Adult

Interventions

Selinexor; Venetoclax; Azacitidine

Participants

6

Sites

1

Countries

China

Trials that died the same way

• Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients
  “The number of enrolled subjects did not meet the goal during the study” (76% match in meaning)
• Body Composition and Lifestyle Factors in ROTC
  “The study did not enroll participants” (69% match in meaning)
• H-29 DELTA Multihole TT Study.
  “Lack of progress in fulfilling the Study activities, including the lack of enrollment of participants” (68% match in meaning)
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
  “Study design was inadequate and would not achieve study endpoints” (67% match in meaning)
• Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
  “the study had a low accrual rate” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.